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Fluids and barriers of the CNS establish immune
privilege by confining immune surveillance to a
two-walled castle moat surrounding the CNS castle
Britta Engelhardt*, Caroline Coisne
Abstract
Neuronal activity within the central nervous system (CNS) strictly depends on homeostasis and therefore does not
tolerate uncontrolled entry of blood components. It has been generally believed that under normal conditions, the
endothelial blood-brain barrier (BBB) and the epithelial blood-cerebrospinal fluid barrier (BCSFB) prevent immune
cell entry into the CNS. This view has recently changed when it was realized that activated T cells are able to
breach the BBB and the BCSFB to perform immune surveillance of the CNS. Here we propose that the immune
privilege of the CNS is established by the specific morphological architecture of its borders resembling that of a
medieval castle. The BBB and the BCSFB serve as the outer walls of the castle, which can be breached by activated
immune cells serving as messengers for outside dangers. Having crossed the BBB or the BCSFB they reach the
castle moat, namely the cerebrospinal fluid (CSF)-drained leptomeningeal and perivascular spaces of the CNS. Next
to the CNS parenchyma, the castle moat is bordered by a second wall, the glia limitans, composed of astrocytic
foot processes and a parenchymal basement membrane. Inside the castle, that is the CNS parenchyma proper, the
royal family of sensitive neurons resides with their servants, the glial cells. Within the CSF-drained castle moat,
macrophages serve as guards collecting all the information from within the castle, which they can present to the
immune-surveying T cells. If in their communication with the castle moat macrophages, T cells recognize their
specific antigen and see that the royal family is in danger, they will become activated and by opening doors in the
outer wall of the castle allow the entry of additional immune cells into the castle moat. From there, immune cells
may breach the inner castle wall with the aim to defend the castle inhabitants by eliminating the invading enemy.
If the immune response by unknown mechanisms turns against self, that is the castle inhabitants, this may allow
for continuous entry of immune cells into the castle and lead to the death of the castle inhabitants, and finally
members of the royal family, the neurons. This review will summarize the molecular traffic signals known to allow
immune cells to breach the outer and inner walls of the CNS castle moat and will highlight the importance of the
CSF-drained castle moat in maintaining immune surveillance and in mounting immune responses in the CNS.
Introduction
Traditionally, the central nervous system (CNS) was
viewed as an immunologically-privileged site, which was
interpreted as the complete absence of immune surveil-
lance of this tissue [1]. The theoretical basis of these
considerations were that CNS homeostasis, which is
required for the proper communication of neurons,
would not tolerate routine immune cell patrolling in
their search for relevant antigens. Experimental findings
supporting this notion were that allo- and xenogenic
(from different species) tissue grafts, when transplanted
into the CNS are much less efficiently rejected by the
recipient when compared to transplantation to orthoto-
pic (original) sites. Additionally, the CNS parenchyma is
devoid of cells constitutively expressing MHC class I
and II and therefore the molecules required by T cells
to recognize their antigen. In addition, the CNS lacks
lymphatic vessels and thus the commonly established
pathways of the afferent communication arm of the
immune system. Finally, it was thought that the efferent
arm of the immune system to the CNS was completely
blocked by the endothelial blood-brain barrier (BBB)
and the epithelial blood-cerebrospinal fluid barrier
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(BCSFB) establishing the barriers between the changing
blood milieu and the CNS. The view of immunological
ignorance of the CNS has, however, been in conflict with
observations by Medawar and colleagues that an allo-
genic tissue graft into the brain, which would be tolerated
in a naive host, was readily rejected in a recipient which
was sensitized to the allo-antigens before the transplanta-
tion [2]. These observations suggested that T cells acti-
vated outside the CNS found a way across the brain-
barriers and mounted an immune response within the
CNS. Subsequent observations in a number of immune-
mediated CNS pathologies including chronic inflamma-
tory diseases such as multiple sclerosis and its animal
model, experimental autoimmune encephalomyelitis
(EAE), made it obvious that the view of immune privilege
for the CNS as the absence of immune surveillance, was
in fact too far reaching. In contrast to multiple sclerosis,
the etiology of EAE is well established as is it induced by
the intravenous transfer of activated neuro-antigen-speci-
fic T cell blasts or by subcutaneous immunization with
myelin antigens in susceptible animals. As induction of
EAE does not require any manipulation of the CNS
proper, this animal model has proven to be very valuable
for studying immune cell entry into the CNS. By studying
EAE we have learned that activated T cells can indeed
migrate across either the BBB or the BCSFB in the
absence of CNS inflammation and enter the cerebrosp-
inal fluid (CSF)-drained leptomeningeal and perivascular
spaces. Therefore we propose that the immune privilege
of the CNS is established by a unique architecture resem-
bling that of a medieval castle. In this view the CSF space
resembles the castle moat of a medieval castle, which is
bordered at the outside by the BBB and the BCSFB - the
outer castle wall- and towards the inside by the glia lim-
itans - the inner castle wall. Inside the castle, that is the
CNS parenchyma proper, the royal family of sensitive
neurons resides with their servants, the glial cells.
Immune surveillance is restricted to the castle moat,
where perivascular and meningeal macrophages serve as
guards that continuously collect information from within
the castle, and present this information to the messengers,
the T cells. If in their communication with the castle
moat guards, T cells recognize their antigen they will
become activated and open gates in the outer castle wall
allowing the entry of more immune cells from outside.
Within the castle moat the immune cells then mount an
invasion of the castle, breaching the inner castle wall and
entering the castle with the aim to eliminate any intru-
ders. If for reasons unknown, T cells turn their attack to
the inhabitants of the castle, chronic immune cell inva-
sion of the castle will eventually kill many of the castle
inhabitants leading to neuronal deficits as observed in
chronic neuroinflammatory diseases of the CNS such as
multiple sclerosis [3].
Architecture of the brain barriers: the castle walls
and the castle moat
Brain barriers are composed of the endothelial blood-
brain barrier (BBB) and the epithelial blood-cerebrosp-
inal fluid barrier (BCSFB), which protect the CNS from
the changing milieu of the periphery. The BBB is
formed by highly-specialized endothelial cells that tightly
restrict the paracellular and transcellular passage of
hydrophilic molecules into the CNS by an elaborate net-
work of complex tight junctions between the endothelial
cells, in conjunction with a lack of fenestrations and low
pinocytotic activity [4]. To fulfill the high metabolic
requirements of the CNS parenchyma, sophisticated
transport mechanisms operate in BBB endothelial cells
ensuring the transport of nutrients from the blood into
the CNS and the rapid extrusion of toxic metabolites
out of the CNS [5].
Besides the BBB, epithelial cells of the choroid plexus
establish the BCSFB, taking over similar functions as the
BBB. The choroid plexus, which secretes the cerebrosp-
inal fluid (CSF), consists of villous structures that extend
from the ventricular surfaces into the lumen of the ven-
tricles. It is formed by an extensive network of fene-
strated capillaries, enclosed by a monolayer of cuboidal
epithelium. In contrast to the CNS parenchyma, where
microvessels establish the BBB, the microvessels within
the choroid plexus stroma are fenestrated allowing the
free diffusion of solutes between the blood and the
choroid plexus parenchyma through inter-endothelial
gaps (reviewed in [6]). The actual barrier that inhibits
free diffusion of water-soluble molecules between the
bloodstream and the CNS is formed by the choroid
plexus epithelial cells that display unique parallel tight
junctions [7,8]. Again, similar to the BBB, the barrier
and secretory functions of the choroid plexus epithelial
cells are maintained by the polarized expression of a
number of specific transmembrane transport systems
that allow directed transportation into the CSF and the
removal of toxic agents out of the CSF [6].
Proper function of the BBB has been shown to rely
critically on the sustained interaction with the adjacent
extracellular matrix components and cellular elements
[9]. The fully-differentiated BBB has therefore recently
been referred to as the neurovascular unit (NVU).
Within the NVU the highly specialized endothelial cells
are the basis of the BBB, which is supported by an
underlying endothelial basement membrane embedding
a high number of pericytes [10,11]. A layer of astrocytic
endfeet along with their parenchymal basement mem-
brane are referred to as the glia limitans perivascularis
[4,12]. The glia limitans and the BBB delineate a CSF-
filled space, in which host antigen-presenting cells are
localized [13-15]. At the level of parenchymal vessels
the perivascular space is narrow. The CSF within these
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perivascular spaces drains into the subarachnoid space
on the surface of the brain and the spinal cord [16].
There the CSF space widens as the meningeal blood
vessels lack the direct ensheathment by the glia limitans
perivascularis [17]. However, the CSF-drained subarach-
noid space is also sealed off towards the neuropil by the
glia limitans superficialis, which resembles the glia lim-
itans perivascularis and surrounds the entire surface of
the brain and spinal cord [13]. Nevertheless, meningeal
CNS microvessels also establish a functional BBB [18],
although subtle differences exist between the parenchy-
mal and meningeal BBB, with parenchymal but not
meningeal endothelial cells lacking storage of certain
adhesion molecules in their Weibel Palade bodies
[19,20], suggesting that at the level of the meninges the
BBB might provide some additional cues for immune
cells to reach the CSF-drained leptomeningeal spaces.
In contrast to the BBB, much less is known about how
barrier characteristics of the BCSFB are maintained but
it is reasonable to assume that the CSF provides signals
for BCSFB maintenance. Cells found in tight association
with the apical aspect of the BCSFB have been described
as Kolmer cells or epiplexus cells and are most probably
antigen-presenting cells (reviewed in [8]).
Immune surveillance of the CNS: lessons
from experimental autoimmune
encephalomyelitis (EAE)
Direct evidence for T cell trafficking into the healthy
CNS came from tracing radioactively-labeled encephali-
togenic CD4+ T cell blasts infused into the circulation
of Lewis rat that resulted in the development of experi-
mental autoimmune encephalomyelitis (EAE), consid-
ered to be the best animal model for multiple sclerosis
(MS) (reviewed by [21]).
MS and EAE are characterized by a massive infiltra-
tion of circulating immune cells into the CNS, resulting
in central inflammation, oedema formation and demyeli-
nation, the basis for the onset of the clinical manifesta-
tions of these diseases. Both diseases show clinical and
histopathological similarities, however, whereas MS
etiology remains unclear and shows a great variety of
neuropathological changes, EAE is a T cell-mediated
autoimmune inflammatory disease with a well-described
CNS pathology. The model disease of EAE can be gen-
erated either upon immunization of susceptible naive
recipients with CNS myelin antigens or by intravenous
injection of freshly-activated - but not resting - CNS
myelin-specific CD4+ T cell subsets [22], supporting the
concept that only activated T cells can breach the BBB
or BCSFB to reach the CSF-filled spaces, where upon
encounter of the antigen-presenting cells they can trig-
ger the molecular events leading to the development of
the clinical manifestations of the disease.
It has therefore been recognized that the interaction of
CD4+ T lymphoblasts with the healthy brain barriers
represents the critical step in the initiation of the dis-
ease. Few studies have, however, directly addressed the
molecular mechanisms of T lymphoblast migration
across the BBB. We have approached this question by
means of intravital microscopy (IVM) of the spinal cord,
a technique that allowed us to directly observe the inter-
action of circulating fluorescently-labeled encephalito-
genic T cell blasts with the spinal cord microvasculature
[23]. Using this technique, our laboratory demonstrated
that freshly-activated encephalitogenic Th1 cell blasts
are able to interact with spinal cord capillaries and post-
capillary venules in healthy animals [23]. Th1 cell inter-
action with the non-inflamed BBB occurred in post-
capillary venules and was found to be unique due to a
lack of rolling. Rather, encephalitogenic Th1 cell blasts
were abruptly captured to the spinal cord post-capillary
venule wall, followed by firm adhesion of the Th1 cell
to the venule [23]. Both capture and firm adhesion were
found to be mediated through the interaction of a4-
integrins on the Th1 cell with endothelial VCAM-1,
whereas diapedesis of Th1 cells across the venule wall
was found to be supported by the aLb2-integrin (leuko-
cyte function-associated antigen (LFA)-1) [24]. However,
successful diapedesis of Th1 cells into the perivascular
space across the intact BBB was only observed at 4 to 6
hours post-injection [24] suggesting that breaching the
healthy BBB remains difficult. Although we observed
a4-integrin/VCAM-1-dependent capillary plugging of
Th1 cells, Th1 cell diapedesis was solely observed at the
level of spinal cord post-capillary venules. In fact, IVM
studies of T cell interaction with the non-inflamed
blood-retinal barrier, which displays tight junctions and
barrier characteristics comparable to the BBB, provided
similar observations [25]. T cell blasts were also
observed to abruptly stop without prior rolling within
non-inflamed retinal microvessels and to take up to 16
hours to penetrate the vascular wall. These authors
found that successful diapedesis of T cell blasts across
the blood-retinal barrier required local activation of
endothelial cells as demonstrated by the upregulation of
the intercellular adhesion molecule-1 (ICAM-1) on the
endothelial surface that is required for T cell diapedesis
across vascular barriers [25]. Thus, T lymphoblast entry
across the parenchymal BBB seems to be a difficult task
and only few T cells seem to reach the perivascular
space, which raises the question whether T lymphoblast
extravasation across the BBB would be sufficient to
ensure the immune surveillance of the entire CNS.
Therefore, other routes of T cell entry into the healthy
CNS need to be considered. In fact, in vivo homing stu-
dies following fluorescently labeled encephalitogenic T
cell blasts, showed that two hours following their
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systemic injection these cells were already found within
the leptomeningeal compartment [26]. The molecular
key allowing for T cell entry into this compartment was
defined to be P-selectin, which is stored in Weibel-
Palade bodies in endothelial cells of leptomeningeal, but
not parenchymal BBB, endothelial cells [27,28]. Thus, P-
selectin seems to provide easier access for T cell blasts
into the leptomeningeal space, whereas in the absence
of P-selectin at the level of the parenchymal BBB, entry
of T cells into the narrow perivascular space is less effi-
cient as it takes longer and requires different molecular
keys as outlined above. T cells, which have entered the
CSF-drained subarachnoid space, where they perform
immune surveillance of the CNS-drained leptomeningeal
space, start to screen leptomeningeal macrophages for
their specific antigen. Recently, two-photon imaging stu-
dies of the rat spinal cord microvasculature from
Bartholomäus and colleagues confirmed that T cell
blasts preferentially enter the leptomeningeal spaces
[29]. However, without any specific antigen-triggering,
activated T cells were restricted to the leptomeningeal
space, as they did not manage to make their way
through the glia limitans into the CNS parenchyma
[29,30].
Following fluorescently-labeled encephalitogenic T cell
blasts in vivo also detected T cells within the choroid
plexus parenchyma two hours following their systemic
injection [26]. Similar to the meningeal BBB, P-selectin
was found to be expressed on the fenestrated choroid
plexus capillaries [31], suggesting that again P-selectin
may specifically guide T cell blasts into the choroid
plexus. However, T cells that have crossed the choroid
plexus microvasculature are localized within the choroid
plexus stroma and thus still outside of the CNS. To get
access to the CSF drained space these T cells still need
to penetrate the epithelial BCSFB. The observation that
in humans high numbers of central memory T cells are
present within the CSF compartment, when compared
to the peripheral blood of healthy individuals, strongly
suggests that T cells enter the CSF compartment
directly via the choroid plexus across the BCSFB [31,32].
In fact the first molecular explanation of T cell migra-
tion across the BCSFB has been recently provided, when
studying the role of Th17 cells in the pathogenesis of
EAE. Mice deficient for the chemokine receptor CCR6,
which is specifically expressed on the Th17 subset of T
cells, were found to be resistant to EAE [33]. In this
context, CCR6-/- immune cells were found to have accu-
mulated within the choroid plexus parenchyma, where
the chemokine CCL20, the ligand for CCR6, is constitu-
tively produced by the choroid plexus epithelium.
CCL20 is not expressed at the BBB and CCR6 was not
involved in T cell interaction with the BBB. As CCR6-/-
mice developed EAE following the transfer of a
subclinical number of fluorescently-labelled myelin-spe-
cific Th17 cells expressing CCR6, it was concluded that
EAE is initiated by the CCR6/CCL20-dependent migra-
tion of Th17 cells across the non-inflamed BCSFB.
Additional molecular mechanisms of T cell migration
across the BCSFB remain to be investigated. Although
the choroid plexus epithelium constitutively expresses
ICAM-1 and VCAM-1, these molecules are expressed in
a highly polarized fashion at the apical side of the chor-
oid plexus epithelium [34,35] and are therefore not
accessible to T cells migrating across the BCSFB from
the basolateral to the apical side. Once they have pene-
trated the BCSFB, Th17 blasts seem to rapidly travel to
the leptomeningeal spaces, where fluorescently-labelled
CCR6+ Th17 cells were exclusively found within the lep-
tomeningeal compartment [33].
Taken together, these observations demonstrate that
immune surveillance of the CNS is ensured by allowing
activated immune cells access via the BBB and the
BCSFB to the CSF space, where they can interact with
the antigen presenting cells. In the absence of antigen
recognition these T cell blasts remain confined to the
CSF drained spaces and therefore do not impair CNS
homeostasis. However, if they recognize their specific
antigen, these immune cells will mount an inflammatory
response that brings additional immune cells from the
periphery into the perivascular spaces and from there
they eventually breach the glia limitans, to mount an
immune defence within the CNS parenchyma.
T cell invasion in neuroinflammation: Lessons
from experimental autoimmune
encephalomyelitis (EAE)
Reactivation of the T cells, by their antigen-presenting
cells bearing the cognate antigen, within the CSF-filled
CNS spaces will lead to inflammatory changes of the
BBB and probably also of the BCSFB. This is achieved
by the expression of additional trafficking signals on
these barriers allowing the recruitment of numerous
inflammatory cells from the bloodstream into the CSF-
drained perivascular and subarachnoid spaces. The
molecular mechanisms involved in T cell migration
across the inflamed BBB have been well studied using
EAE, the animal model of multiple sclerosis, and will be
summarized here.
Breaching the BBB - the outer castle wall
A number of intravital microscopic studies observing
the interaction of myelin-specific T cells with inflamed
leptomeningeal brain microvessels in EAE have shown
that endothelial P-selectin mediated the rolling of T
cells via their selectin ligand PSGL-1 in leptomeningeal
post-capillary venules [36-39]. Surprisingly though,
numerous studies by us and others demonstrated that
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blocking or absence of PSGL-1 or E- and P-selectin did
not have any significant impact on the recruitment of
inflammatory cells into the CNS and failed to affect the
development of the disease [28,38,40-43]. At the same
time, initial interaction of T cells with the inflamed BBB
is no longer solely dependent on a4b1-integrins,
because functional blockade of a4-integrins on human
T cells or the deletion of the b1-integrin sub-units on
mouse T cells, did not show any impact in the initial
interaction of these T cells with the inflamed spinal
cord microvasculature of mice afflicted with EAE
[44,45]. Because combined blockage of P-selectin and
a4-integrins resulted in a more complete inhibition of T
cell rolling along inflamed leptomeningeal vessels and
produced a greater delay of EAE onset than solely
blocking a4-integrins, it is concluded that P-selectin/
PSGL-1 and a4-integrins/VCAM-1 interactions might
mediate T cell rolling in an overlapping or partially
redundant fashion [38].
Firm arrest of T cells at the inflamed post-capillary
venule BBB similarly requires signalling via G-protein-
coupled receptors present on the surface of the circulat-
ing immune cells, as at the healthy BBB [36]. Thus che-
mokines or eicosanoids displayed on the luminal side of
the BBB are involved in inflammatory cell recruitment
across the BBB during EAE. Although numerous che-
mokines have been shown to be involved in EAE patho-
genesis [46,47], the ones mediating T cell arrest at the
BBB remain to be defined. To date, relatively few che-
mokines have been reported to be expressed by the BBB
endothelium per se. These are the lymphoid chemokines
CCL19 [48-50] and CCL21 that have been shown to
enable the adhesion of encephalitogenic CCR7+ T cells
to inflamed brain microvessels in vitro [48]. Endothelial
expression of CXCL12 is upregulated during EAE, its
increased expression may, however, be more related to
anti-inflammatory effects [51]. Also, CXCL12 expression
is restricted to the basolateral side of the CNS microvas-
cular endothelium, thus facing towards the perivascular
space and suggesting a function in this compartment,
rather than in T cell recruitment across the BBB. In
fact, this chemokine was shown to cause retention of
the inflammatory cells expressing CXCR4 that have
infiltrated the perivascular space [51]. Taken together,
the chemokines involved in T cell migration across the
BBB remain to be defined.
G-protein-mediated activation of integrins on the T
cells leads to their arrest at the post-capillary venule
BBB. Several studies reported the upregulation of the
integrin ligands ICAM-1 and VCAM-1 on CNS
endothelia [36,52-54] as well as on the choroid plexus
epithelium [53] during EAE. In animals afflicted with
EAE, the CNS inflammatory cells localized around
ICAM-1 and VCAM-1-positive venules stain positive for
LFA-1 and a4b1-integrins, the ligands for ICAM-1 and
VCAM-1, respectively. In MS lesions, the upregulation
of ICAM-1 expression was observed on inflamed vessels
[55,56] along with LFA-1-positive staining of most infil-
trating immune cells [56]. In contrast to EAE, VCAM-1
expression was described on CNS microvessels in some
[57] but not in other [58] MS lesions. However, in
human CNS microvessels, the CS1 domain of a spliced
variant of fibronectin (FN-CS1) could serve as an alter-
native ligand for a4-integrin [59].
Numerous in vitro studies have demonstrated that
under static conditions T cells bind via LFA-1 and a4-
integrins to their respective endothelial ligands, ICAM-1
and VCAM-1, on inflamed cerebral vessels in a Stam-
per-Woodruff assay [53,60] or on cultured brain micro-
vascular endothelial cells [59,61-64]. Recent elegant in
vitro and in vivo studies have specified that shear-resis-
tant T cell arrest on the inflamed BBB is mediated by
LFA-1/ICAM-1 and a4b1-integrin/VCAM-1 interactions
[29,45,65].
The development of EAE can be abrogated by block-
ing a4-integrins or VCAM-1 as shown by many labora-
tories [54,60,66-68]. The therapeutic effect of these
blocking antibodies leads to the inability of the immune
cells to breach the BBB and has been successfully trans-
lated into the clinic, where the humanized monoclonal
antibody against a4-integrins, natalizumab is success-
fully used to treat relapsing-remitting MS (summarized
in [69]). We recently demonstrated by means of intravi-
tal microscopy (IVM) that natalizumab specifically inhi-
bits the adhesion, but not the rolling or capture, of
human T cells with the inflamed spinal cord microvas-
culature in mice with acute EAE [44], providing the first
direct in vivo proof of concept of this therapy in MS.
Despite the proven contribution of LFA-1 and its
endothelial ligands ICAM-1 and ICAM-2 in T cell arrest
on the inflamed BBB endothelium, their functional inhi-
bition or absence in a variety of EAE models produced
contradictory results, ranging from inhibiting EAE to
increasing severity of EAE or having no effect at all
[70-72]. Therefore, further investigations will be neces-
sary to fully delineate the role of LFA-1 and its ligands
ICAM-1 and ICAM-2 beyond their mere contribution
to T cell trafficking across the BBB.
Recent elegant in vitro and in vivo studies demon-
strated that once T cells have arrested on the BBB sur-
face, T cells get polarized and start to crawl on the
endothelium against the direction of the blood flow
until they find sites permissive for diapedesis [29,65]. T
cell polarization and crawling is mediated by LFA-1
binding to endothelial ICAM-1 and ICAM-2 with no
further contribution of a4-integrin/VCAM-1 [61,65,73].
Binding of LFA-1 to endothelial ICAM-1 was shown to
trigger signaling cascades in brain endothelial cells
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leading to the activation of the tyrosine kinase p60,
phosphorylation of cortactin, to intracellular calcium
increase and RhoA activation, all triggering the reorgani-
zation of the endothelial actin-cytoskeleton (summarized
in [74]). Nevertheless, although diapedesis of T cells
across the BBB seems to be more efficient in the
presence of ICAM-1 and ICAM-2 [75], passage of T
cells can be observed in the absence of ICAM-1 and
ICAM-2, suggesting that additional molecular cues can
be used by T cells for diapedesis across the BBB, or that
alternative pathways exist. We and others who have
investigated leukocyte diapedesis across the BBB into
the inflamed CNS by means of transmission electron
microscopy have invariably observed leukocyte migra-
tion to occur through the endothelial cells, i.e. via a
transcellular pathway, leaving the tight junctions intact
[76-81]. However, other researchers studying T cell dia-
pedesis across the BBB in vitro have doubted this view
and support the view that paracellular diapedesis occurs
through the BBB tight junctions (summarized in [76]).
At present, the molecular mechanisms guiding transcel-
lular or paracellular diapedesis of T cells across the
inflamed BBB are not well understood and have rarely
been specifically addressed in the context of the BBB.
One exception is the endothelial junctional molecule
PECAM-1. PECAM-1-/- mice show increased infiltration
of immune cells across the BBB along with an enhanced
vascular permeability [82] demonstrating that impair-
ment of endothelial junctions at the BBB might favor a
paracellular pathway for T cell diapedesis. Thus, the
molecular mechanisms of the multistep recruitment of
T cells across the inflamed BBB are not yet fully under-
stood and the role of additional molecules such as JAM-
A [83] or ALCAM [84], which have been suggested to
be involved in these processes need to be explored in
more detail.
Following their diapedesis across the inflamed BBB, T
cells need to make their way across the acellular extra-
cellular matrix components of the endothelial basement
membrane. The endothelial basement membrane con-
sists of a number of glycoproteins such as laminins,
collagen type IV, nidogens, and heparan sulfate proteo-
glycans. Recently, it has been observed that T cell extra-
vasation at the BBB occurs preferentially at sites, where
the endothelial basement membrane contains laminin
a4 rather than laminin a5 [12,85]. In laminin a4-defi-
cient mice, compensatory expression of laminin a5 is
found in the endothelial cell basement membranes
of the CNS and in these mice, EAE progression was
ameliorated in association with a reduction of cellular
infiltrates [85]. These findings suggest that laminin
a5 does not support T cell migration across the BBB
basement membrane and may even redirect T cells to
specific sites devoid of this laminin isoform, where
a6b1- integrin/laminin a4 binding will facilitate the
transmigration of T lymphocytes across the endothelial
basement membrane into the perivascular space [85].
In contrast to the BBB, the molecular mechanisms for
T cell diapedesis across the BCSFB during EAE have not
been investigated. During EAE, upregulated expression
of functional ICAM-1 and VCAM-1 and induction of
MAdCAM-1 is observed [34]. As these molecules are
exclusively expressed on the apical side of the choroid
plexus epithelium [35], they are not accessible for T
cells crossing the BCSFB from the basolateral to apical
sides. Also, in most neuroinflammatory disorders, accu-
mulation of immune cells in the choroid plexus cannot
be observed suggesting that this entry port may be more
relevant during immune surveillance.
Immune cells in the CSF-drained fluid spaces - the
castle moat
Once the endothelial basement membrane has been
breached, extravasating encephalitogenic T cells reach
the perivascular space, where they have to re-encounter
their cognate antigen presented by antigen-presenting
cells, in the context of major histocompatibility complex
(MHC) class II, in order to pursue their route into the
CNS parenchyma. This was demonstrated by the study
from Greter and colleagues, in which the clinical devel-
opment of EAE was shown to be triggered by myelin-
reactive T cells following antigen priming by perivascu-
lar CD11c+ dendritic cells [15]. A recent elegant two-
photon in vivo imaging study demonstrated that T cells
interact with many leptomeningeal macrophages in
search of their specific antigen [29]. In the absence of
their specific antigen, T cells were confined to this
space, whereas upon recognition of their specific antigen
they could invade the CNS parenchyma.
In EAE it has been demonstrated that the typical peri-
vascular inflammatory cuffs are localized between the
outer endothelial and inner parenchymal basement
membranes, and therefore remain within the perivascu-
lar space. Interestingly, clinical signs of EAE only
start following the penetration of inflammatory cells
across the glia limitans and their entry into CNS
parenchyma [86].
Attack of the CNS requires breaching of the glia
limitans, the inner wall of the castle
The CSF-drained perivascular and subarachnoid spaces
are sealed off towards the neuropil by the glia limitans
perivascularis and glia limitans superficialis, respectively,
surrounding the entire surface of the brain and spinal
cord [13]. The glia limitans is composed of the parench-
ymal basement membrane, which is molecularly distinct
from the endothelial basement membrane with deposi-
tion of laminins a1 and a2 but not the endothelial
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laminins a4 and a5 (summarized in [9]). The parenchy-
mal basement membrane is laid down by astrocytes
which with their foot processes, embrace the entire sur-
face of the CNS parenchyma.
In contrast to the penetration of the BBB, penetration
of the glial limitans by inflammatory cells requires the
activity of matrix metalloproteinases (MMP-2 and
MMP-9), which is probably due to the distinct biochem-
ical composition of the parenchymal basement mem-
brane and the tight seal with astrocyte foot processes
[86]. Obviously, MMP-2 and MMP-9 are produced by
the myeloid cells surrounding the T cells in the perivas-
cular space [86] and allow immune cells to breach the
glia limitans and reach the CNS parenchyma where
they start their attack on the CNS parenchymal cells.
Once immune cells have reached the CNS parenchyma
the immune attack starts and CNS parenchymal cells
may be sacrificed in order to fight the potential infec-
tion. In EAE the autoimmune response leads to chronic
attack of oligodendrocytes and neurons eventually lead-
ing to demyelination and axonal loss, that is to say ulti-
mately the loss of CNS neurons.
Conclusion
Originally the CNS was considered an immune-privi-
leged organ in the sense that it is ignored by the
immune system. Recent studies on T cell trafficking to
the CNS in the context of EAE have identified anatomi-
cal routes and molecular mechanisms of T cell entry
into the CNS during health and disease and suggest that
CNS immune privilege is accomplished by the unique
architecture of a medieval castle that is surrounded by a
two-walled moat. Activated memory/effector but not
resting T cells, are in possession of the molecular
keys to breach the outer castle wall - the BBB or the
BCSFB - without impairing its resistance to assault.
Behind this outer cellular barrier, T cells enter the CSF
drained ventricular, perivascular and subarachnoidal
spaces, which are bordered by two biochemically distinct
basement membranes. Immune-surveillance of the CNS
is confined to this space, which resembles the castle
moat bordered by outer and inner walls and patrolled
by guards, the perivascular antigen-presenting cells and
the epiplexus cells. If T cells encounter their specific
antigen within the CSF-drained castle moat, they
become activated and will trigger an inflammatory
response that leads to the upregulation of novel traffic
signals on the BBB and the BCSFB - i.e. opening doors
in the outer wall and leading to the recruitment of addi-
tional inflammatory cells across this outer barrier.
Production of cytokines and proteases allows the degra-
dation of the glia limitans - the inner wall of the castle
moat - and in a second step by lowering the draw-bridge
across the castle moat, large number of infiltrating
inflammatory cells will then enter the CNS parenchyma,
leading to the cellular assault of the castle, respectively.
Taken together, it has been realized that the CSF-drained
fluid spaces play a central role in establishing CNS
immune surveillance and therefore in maintaining CNS
immune privilege. Whereas our understanding of the
traffic signals involved in T cell migration across the BBB
has increased enormously, T cell entry across the BCSFB
and the following steps of immune cell entry across the
basement membranes and the glia limitans remain to be
investigated.
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